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Recent large-scale transcriptome analyses have revealed that transcription is spread
throughout the mammalian genomes, yielding large numbers of transcripts, including
long non-coding RNAs (lncRNAs) with little or no protein-coding capacity. Dozens of
lncRNAs have been identiﬁed as biologically signiﬁcant. In many cases, lncRNAs act as
key molecules in the regulation of processes such as chromatin remodeling, transcription,
and post-transcriptional processing. Several lncRNAs (e.g., MALAT1, HOTAIR, and ANRIL)
are associated with human diseases, including cancer. Those lncRNAs associated with
cancer are often aberrantly expressed. Although the underlying molecular mechanisms by
which lncRNAs regulate cancer development are unclear, recent studies have revealed that
such aberrant expression of lncRNAs affects the progression of cancers. In this review, we
highlight recent ﬁndings regarding the roles of lncRNAs in cancer biology.
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INTRODUCTION
As biological complexity increases and their genome sizes have
increased, organisms have acquired non-coding regions in their
genomes (Taft and Mattick, 2003). In the human genome, the
ratio of non-coding DNA to total genomic DNA is approxi-
mately 98.5%. Recent studies have revealed that transcription is
not restricted to protein-coding regions, but occurs throughout
the genome (>90%), including non-coding regions. This yields
large numbers of non-coding RNAs (ncRNAs; Birney et al., 2007).
Increasingly, functional roles for these ncRNAs are being identi-
ﬁed. Therefore, the discovery of these abundant ncRNAs should
expand our understanding of the mechanisms underlying many
biological processes.
Non-coding RNAs are mainly classiﬁed as housekeeping or reg-
ulatory ncRNAs. Housekeeping ncRNAs include transfer RNAs
(tRNAs), ribosomal RNAs (rRNAs), and spliceosomal RNAs.
These housekeeping ncRNAs are usually expressed constitutively
in cells and are necessary for vital cellular functions. Regulatory
ncRNAs are speciﬁcally expressed during certain developmental
stages, and in certain tissues or diseases. Based on transcript size,
regulatory ncRNAs can be further grouped into two subclasses:
small ncRNAs (20–200 nt), and long ncRNAs (lncRNAs,>200 nt).
MicroRNAs (miRNAs) represent a type of small ncRNA. miRNAs
are involved in biological processes such as development, differen-
tiation, and diseases (e.g., cancer) via gene silencing, establishing
their biological signiﬁcance (Mattick and Makunin, 2005).
Recently, functional analyses of lncRNAs have commenced
in this emerging ﬁeld of molecular biology. Although our cur-
rent understanding of the functional role of lncRNAs is limited,
recent reports have revealed characteristics and novel functions
of these molecules. Diverse functions of lncRNAs include their
involvement in the integrity of the nuclear structure, regulation of
gene expression, chromatin remodeling, transcription, and post-
transcriptional processing (Mercer et al., 2009;Wilusz et al., 2009).
An example of this is the lncRNA NEAT1, which is essential for the
organization of paraspeckle structure (Clemson et al., 2009; Sasaki
et al., 2009). Xist and Kcnq1ot1 are examples of lncRNAs involved
in chromatin remodeling, where they recruit the polycomb com-
plex to the X chromosome or the Kcnq1 domain, respectively.
They induce heterochromatin formation and repress gene expres-
sion (Silva et al., 2003; Pandey et al., 2008). Through regulation of
chromatin remodeling, Xist RNA inactivates the X chromosome
andKcnq1ot1 establishes lineage-speciﬁc transcriptional silencing
patterns. It is assumed that lncRNAs exert their functions by reg-
ulating the localization or activity of proteins through interaction
with speciﬁc RNA binding proteins. Recently, two independent
studies focused on the stability of lncRNAs and revealed the
relationships between half-lives of lncRNAs and their functions.
Interestingly, the half-lives of lncRNAs vary over a similarly wide
range to that of mRNAs. Those lncRNAs with a short half-life
include known regulatoryncRNAs,while thosewith a longhalf-life
are involved with housekeeping functions (Clark et al., 2012; Tani
et al., 2012). Considering those characteristics and effects on cellu-
lar andmolecularmechanisms,we cannot exclude the involvement
of lncRNAs from future analyses of biological process and disease
pathogenesis.
Recently, several lncRNAs have been identiﬁed as being cancer-
speciﬁc. It is possible these lncRNAs can be harnessed as novel
biomarkers or therapeutic targets. In this review,we focus on some
well-characterized lncRNAs associated with the progression of
cancer, namely metastasis-associated lung adenocarcinoma tran-
script 1 (MALAT1), HOX antisense intergenic RNA (HOTAIR),
and antisense non-coding RNA in the INK4 locus (ANRIL).
METASTASIS-ASSOCIATED LUNG ADENOCARCINOMA
TRANSCRIPT 1 (MALAT1)
MALAT1, also knownasNEAT2 (nuclear-enriched abundant tran-
script 2),was the lncRNA thatwas originally found to be associated
with lung cancer (Ji et al., 2003). MALAT1 is an lncRNA of more
than 8000 nt. In the human genome, MALAT1 is located on
chromosome 11q13, a region known to be relevant to tumori-
genesis and metastasis. Ji et al. (2003) found that MALAT1 was
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overexpressed in early-stagemetastasizing non-small cell lung can-
cer (NSCLC). High expression levels of MALAT1 correlated with
poor prognosis in NSCLC patients. Therefore, MALAT1 has been
proposed as a prognosticmarker formetastasis andNSCLCpatient
survival.
MALAT1 has several unique features. Intracellularly, MALAT1
is stably retained in the nucleus (Miyagawa et al., 2012). We
have previously found that the half-life of MALAT1 RNA is
around 7.6 h, classifying it as a long-lived non-coding tran-
script (Tani et al., 2012). The 3′ end of the MALAT1 transcript
is cleaved by tRNA processing machinery to yield a tRNA-like
small RNA, known as MALAT1-associated small cytoplasmic RNA
(mascRNA); however, it localizes to the cytoplasm, has a relatively
short half-life, and its function remains unknown (Wilusz et al.,
2008). After processing in the nucleus,mascRNA is exported to the
cytoplasm,while the abundant and stableMALAT1 long transcript
remains in the nucleus.
In the nucleus, MALAT1 speciﬁcally localizes to nuclear speck-
les; subnuclear structures that are enriched for pre-mRNA splicing
factors (Hutchinson et al., 2007). Several studies have shown that
nuclear speckles function as storage, assembly and modiﬁcation
compartments, supplying splicing factors to active transcription
sites (Lamond and Spector, 2003). MALAT1 has been shown to
regulate alternative splicing by modulating the distribution and
levels of active pre-mRNA splicing factors (SR proteins) (Tri-
pathi et al., 2010). This is the ﬁrst report showing that MALAT1
directly associates with SR proteins, which are enriched in nuclear
speckles, and regulates gene expression post-transcriptionally.
Unlike NEAT1 lncRNA, which has been shown to be critical
for the integrity of paraspeckles, MALAT1 is not essential for
the integrity of nuclear speckles. Depletion of MALAT1 does
not affect the localization of nuclear speckle markers (Clemson
et al., 2009). MALAT1 appears to be speciﬁcally involved in gene
regulation by modulating the association of SR proteins with
speckles.
MALAT1 is also involved in regulated transcriptional programs
(Yang et al., 2011a). It has been shown to regulate relocation
of growth-control genes from the repressive environment of
polycombbodies (PcGs) to the gene activationmilieu of interchro-
matin granules (ICGs) in response to growth signals by interacting
with unmethylated Pc2. This leads to the promotion of E2F1
SUMOylation and activation of transcription for genes associated
with growth control. Thus, MALAT1 is thought to have a variety
of functions, especially in gene regulation (Figure 1).
Although MALAT1 is highly conserved among mammals and
is broadly expressed in normal mouse and human tissues (Ji et al.,
2003), it is not essential for mouse development (Nakagawa et al.,
2012). MALAT1 might play key roles under certain types of exter-
nal stimuli. MALAT1 is overexpressed not only in lung cancer,
but also in breast, pancreas, colon, prostate, and liver cancers
(Lin et al., 2007) (Table 1), implying key roles in cancer progres-
sion. Our group suggested that MALAT1 promotes lung cancer
cell motility, which is important for metastasis, through regula-
tion of motility-related genes such as CTHRC1, CCT4, HMMR,
and ROD1, transcriptionally and/or post-transcriptionally (Tano
et al., 2010). Schmidt et al. (2011) showed that decreased expres-
sion of MALAT1 in NSCLC xenografts led to impaired tumor
formation and growth. These reports suggested that MALAT1
is a potent player in the metastasis process. In other types of
cancer cells, such as CaSki cervical cancer cells, MALAT1 is
involved not only in cell migration, but also in cell growth
and cell cycle progression (Guo et al., 2010). Another report
demonstrated that MALAT1 promotes epithelial-to-mesenchymal
transition (EMT) by activating the Wnt/β-catenin pathway in
bladder cancer cells (Ying et al., 2012). These reports support the
hypothesis that MALAT1 is an activator for metastasis and affects
metastatic processes. Further investigations are necessary to deter-
mine the precise mechanism(s) of metastatic progression effected
by MALAT1.
HOX ANTISENSE INTERGENIC RNA (HOTAIR)
HOTAIR is also known as metastasis-associated lncRNA (Gupta
et al., 2010). This is a 2.2-kb transcript. Gupta et al. (2010) ﬁrst
revealed that expression of HOTAIR was increased in primary
breast tumors and metastases. They showed a positive correlation
among high expression levels of HOTAIR, subsequent metastasis
and death. Moreover, HOTAIR promotes invasion of breast carci-
noma cells and lungmetastasis in vivo. These ﬁndings indicate that
HOTAIR is a powerful predictor of metastasis and poor prognosis.
Ultra-high-densityHOX tiling array analysis revealed thatmore
than 200 ncRNAs were transcribed from the four human HOX
loci (HOXA–HOXD) (Rinn et al., 2007). HOTAIR lncRNA is a
HOX ncRNA transcribed in an antisense manner from the HOXC
locus. Rinn et al. (2007) also revealed that HOTAIR induces tran-
scriptional silencing of the HOXD locus on chromosome 2 by
interacting and recruiting the polycomb repressive complex 2
(PRC2) to the HOXD locus. PRC2, comprising histone H3 lysine
27 (H3K27) methylase EZH2, SUZ12, and EED, establishes the
repressive H3K27me3 chromatin mark and is involved in devel-
opmental gene silencing and cancer progression. Gupta et al.
(2010) showed that overexpression of HOTAIR in epithelial can-
cer cells induced genome-wide re-targeting of PRC2. This led to
altered H3K27 methylation and gene expression. Genes that were
repressed by HOTAIR included tumor suppressor genes, such as
cell adhesion molecules of the protocadherin (PCDH) family and
JAM2. Repressions of those genes were suppressed by concomitant
PRC2 depletion, suggesting PRC2 dependency. This regulation
might be involved in the mechanism by which HOTAIR pro-
motes cancer metastasis. Kogo et al. (2011) found that there was
a close correlation between HOTAIR expression and PRC2 occu-
pancy in patients with colorectal cancer who have metastases and
poor prognosis. Their report also supported the idea thatHOTAIR
reprograms the chromatin state via regulation of PRC2, thereby
promoting cancer metastasis.
On the other hand, the HOXD region is also bound by
CoREST/REST repressor complexes, which contain LSD1, a
demethylase thatmediates enzymatic demethylation of H3K4me2.
Subsequent analysis revealed that HOTAIR also binds to the
LSD1/CoREST/REST complex (Tsai et al., 2010). A 5′ domain of
HOTAIR binds to PRC2, whereas a 3′ domain of HOTAIR binds
to the LSD1 complex. Thus, HOTAIR is a modular bifunctional
lncRNA that has distinct binding domains for a histone methylase
and a demethylase. It can be assumed that HOTAIR serves as a
scaffold for at least two distinct histone modiﬁcation complexes.
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FIGURE 1 | A model for the functions of MALAT1. MALAT1 stably localizes
to nuclear speckles (interchromatin granule clusters; IGCs). (A) MALAT1
regulates alternative splicing by interacting with pre-mRNA splicing factors
(SR proteins) and modulating the distribution and levels of active SR proteins.
(B) MALAT1 regulates relocation of growth-control genes from the repressive
environment of polycomb bodies (PcGs) to the gene activation milieu
of the interchromatin granules (ICGs), in response to growth signals, by
interacting with unmethylated Pc2. This leads to the promotion of E2F1
SUMOylation, and the activation of transcription of genes related to the
control of growth.
Table 1 | Cancer-specific long non-coding RNAs (lncRNAs).
lncRNA Cancer type Function
MALAT1 Lung cancer (Ji et al., 2003; Schmidt et al., 2011) Alternative splicing (Tripathi et al., 2010)
Breast, pancreas, colon, prostate, liver carcinoma (Lin et al., 2007) Gene relocation (Yang et al., 2011a)
Cervical cancer (Guo et al., 2010)
Bladder cancer (Ying et al., 2012)
HOTAIR Breast cancer (Gupta et al., 2010) Chromatin remodeling (Gupta et al., 2010; Tsai et al., 2010)
Colorectal cancer (Kogo et al., 2011)
Hepatocellular carcinoma (Yang et al., 2011b)
Gastrointestinal stromal tumor (Niinuma et al., 2012)
Pancreatic cancer (Kim et al., 2012)
ANRIL Breast cancer (Turnbull et al., 2010) Chromatin remodeling (Yap et al., 2010; Kotake et al., 2011)
Nasopharyngeal carcinoma (Bei et al., 2010)
Glioma (Shete et al., 2009; Cunnington et al., 2010)
Melanoma (Bishop et al., 2009; Cunnington et al., 2010)
Only those cancer-speciﬁc lncRNAs that are described in this review are shown.
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The bifunctional role of HOTAIR may be required for coordinat-
ing histone modiﬁcations in gene silencing to promote metastatic
processes.
Numerous studies have suggested that high expression levels of
HOTAIR in many types of cancer potentially correlate with metas-
tasis and poor prognosis (Kogo et al., 2011; Yang et al., 2011b; Kim
et al., 2012; Niinuma et al., 2012). In a recent study by Kim et al.
(2012), it was demonstrated that HOTAIR is not only a prognos-
tic factor, but also a pro-oncogenic factor in pancreatic cancer.
Further studies should reveal the functions of HOTAIR during
oncogenesis.
ANTISENSE NON-CODING RNA IN THE INK4 LOCUS (ANRIL)
ANRIL was ﬁrst identiﬁed following genetic analysis of familial
melanoma patients with neural system tumors who had a large
germline deletion of the entire INK4B-ARF-INK4A gene cluster
(Pasmant et al., 2007). INK4B-ARF-INK4A gene cluster occupies
a 42-kb stretch on chromosome 9p21 in humans. This gene locus
is homozygously deleted or transcriptionally silenced in a wide
range of cancers, with an estimated frequency of approximately
40%, representing one of the most frequently altered genes in
human cancer. This locus encodes two cyclin-dependent kinase
inhibitors (p15INK4B and p16INK4A) and a regulator of the p53
pathway (p14ARF). The tumor suppressors p15INK4B, p16INK4A,
and p14ARF are frequently disabled in human cancers, including
familial cutaneous malignant melanoma. They inhibit cell cycle
progression and inﬂuence key physiological processes, such as
replicative senescence, apoptosis, and self-renewal of stem cells
(Gil and Peters, 2006). The INK4B-ARF-INK4A locus is regulated
by PRCs and ANRIL is reported to be involved in silencing of this
locus.
ANRIL spans a region of 126.3 kb, and is transcribed as a
3.8-kb lncRNA in the opposite direction from the INK4B-ARF-
INK4A gene cluster (Pasmant et al., 2007). ANRIL has 19 exons,
with two exons of INK4B overlapping. The ﬁrst exon of ANRIL
is located −300 bp upstream of the transcription start site of
ARF. A stronger positive correlation exists between the expression
of ANRIL and ARF in normal human tissue and tumors. These
results suggest that these two genes share a bidirectional promoter
under physiological and pathological conditions. Several reports
have demonstrated that the ANRIL transcript is processed as alter-
native splice variants, including a circular form of ANRIL RNA
(Folkersen et al., 2009; Burd et al., 2010).
Recent genome-wide association studies have identiﬁedANRIL
as a risk locus for several cancers, including breast cancer, nasopha-
ryngeal carcinoma, basal cell carcinoma, and gliomas (Shete
et al., 2009; Stacey et al., 2009; Bei et al., 2010; Turnbull et al.,
2010; Pasmant et al., 2011). Many single-nucleotide polymor-
phisms (SNPs) have been identiﬁed in the ANRIL locus. These
are highly associated with the expression of ANRIL. Cunnington
et al. (2010) revealed that the glioma risk allele SNP rs1063192-
C is highly correlated with increased ANRIL expression, while
the melanoma risk variant SNP rs1011970-T correlated with
decreased expression of ANRIL. Chromosome 9p21 SNPs are
known to correlate with susceptibility to glioma and malignant
melanomas (Bishop et al., 2009; Shete et al., 2009; Wrensch et al.,
2009). Other SNPs in the ANRIL locus have also been reported to
be associated with its expression and involvement in susceptibility
to coronary artery disease (Liu et al., 2009). Although the pre-
cise molecular mechanism(s) by which ANRIL inﬂuences cancer
progression is largely unknown, it is assumed that SNPs mod-
ulate its expression and that this may lead to susceptibility to
cancers.
Recently, two reports have provided mechanistic insights into
the molecular functions of ANRIL during epigenetic transcrip-
tional repression. Kotake et al. (2011) reported that ANRIL binds
to SUZ12 and recruits PRC2 to repress expression of the p15INK4B
locus. Depletion of ANRIL caused defects in SUZ12 binding to
the p15INK4B locus, increased the expression of p15INK4B, but not
p16INK4A or p14ARF , and inhibited cellular proliferation. Yap et al.
(2010) showed that ANRIL binds to chromobox 7 (CBX7) within
PRC1 and recruits it to the INK4B-ARF-INK4A gene locus to con-
trol the expression levels of the genes located at this locus, leading
to regulation of cellular senescence. These studies on ANRIL sug-
gest that it has bifunctional roles, serving as a scaffold for both
PRC1 and PRC2, as shown for HOTAIR. Further studies are nec-
essary to elucidate the detailed mechanism(s) regarding epigenetic
transcriptional regulation byANRIL and to reveal its role in cancer
progression.
CONCLUSIONS AND PERSPECTIVES
Cancer is a complex disease, involving various changes in gene
expression. These gene expression changes cause cancer develop-
ment, includingmetastasis, by affecting cell proliferation, invasion,
and angiogenesis. Although large numbers of protein-coding
genes have been shown to affect cancer progression and several
mechanisms that alter the ability to promote cancer progression
have been identiﬁed, the molecular determinants of cancer pro-
gression remain unknown. ncRNAs have provided a new insight
into cancer biology and provided several lines of evidence to
suggest there is a correlation between their expression and pro-
motion of cancers. In addition to the lncRNAs described above,
increasing numbers of lncRNAs have been identiﬁed as being asso-
ciated with cancer, such as αHIF (antisense hypoxia-inducible
factor-1α; Span et al., 2011), HULC (highly upregulated in liver
cancer; Wang et al., 2010), and PCGEM1 (prostate speciﬁc gene
1; Petrovics et al., 2004). Most of these lncRNAs are speciﬁcally
expressed in certain tumors, at different stages of tumor progres-
sion, or in various tissues. These characteristics would suggest that
lncRNAs could represent biomarkers for diagnosis and prognosis,
in accordance with distinct cancer types. In addition, lncRNAs
whose expression is associated with poor prognosis might be
potential therapeutic targets for gene therapy, such as by siR-
NAs. For example, the inhibition of MALAT1, which is associated
with metastasis and poor prognosis, might be an effective ther-
apeutic strategy for metastatic cancer, without affecting normal
cells because it is not necessary for the viability of normal cells.
Recently, Wheeler et al. (2012) reported a novel strategy to elimi-
nate MALAT1 effectively in vivo using antisense oligonucleotides
(ASOs). This result strongly supports the high potential of cur-
ing metastatic cancers by the elimination of MALAT1 using gene
therapy.
Several reports have suggested that lncRNAs can act as key
factors in the regulation of gene expression; therefore, lncRNAs
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can potentially uncover the molecular mechanisms underlying
the development of cancer, thereby leading to new strategies
for cancer therapy. For example, determination of both binding
proteins associated with each lncRNA and the genes regulated
by lncRNAs would reveal the molecular mechanisms underly-
ing cancer development by lncRNAs. Moreover, it is possible
that not only lncRNAs, but also both binding proteins and the
target genes regulated by lncRNAs, could be novel therapeu-
tic targets, which may lead to the development of novel cancer
treatments. The functional analysis of lncRNAs related to can-
cer represents a major task that should be carried out in the near
future.
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